Sepsis
Conditions
Brief summary
The object of the scientific research is the characterization of the pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.
Interventions
DEVICECytosorb® and Oxiris® adsorbents
The pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.
Sponsors
University Clinical Centre of Republic of Srpska
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* diagnosis of SIRS, sepsis and/or septic shock, * older than 18 years, who are being treated with amikacin and/or vancomycin, * length of use of adsorbent at least 12 hours.
Exclusion criteria
* contraindication for hemodiafiltration with adsorbents, * patients under the age of 18, * terminal cancer patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Development of population pharmacokinetic model | One year | Measurement of amikacin and vancomycine serum concentrations in several time points in order to gain pharmacokinetic profiles of previously mentioned drugs and to develop population pharmacokinetic model of amikacin and vancomycin by nonlinear modeling of combined effects in critically ill patients on veno-venous hemodiafiltration with two types of adsorbents. |
Countries
Bosnia and Herzegovina
Contacts
Primary ContactNikolina Spiric, MPharm
Backup ContactPedja Kovacevic, Prof.
Outcome results
None listed